Bleeding complications after hematopoietic stem cell transplantation.
D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D005177:Factor XIII Deficiency / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications* / Q000188:drug therapy; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000401:mortality; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000209:etiology; D013921:Thrombocytopenia / Q000139:chemically induced; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects
D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa